banda transcan 2 2016ul

Title: Fighting resistance in CLL

Project Coordinator:
Eric ELDERING (Netherlands) Academic Medical Center Department of Experimental Immunology, Amsterdam

Project Partners:
Dimitar EFREMOV (Italy) International Centre for Genetic Engineering and Biotechnolog, Monterotondo (Rome)
Alexander EGLE (Austria) Federal Hospital of Salzburg and Paracelsus Medical Private University, Salzburg
Idit SHACHAR (Israel) Weizmann Institute of Science, Rehovot
Stephan STILGENBAUER (Germany) Department of Internal Medicine III, Ulm University, Ulm
Martina SEIFFERT (Germany) German Cancer Research Center (DKFZ) Heidelberg
Florence CYMBALISTA (France) UMR InsermU978/Université Paris 13/ AP-HP GHPSSD Service d’hématologie biologique, Bobigny

Project Abstract:
Background and rationale. Chronic Lymphocytic Leukemia is a common cancer of mostly elderly people, and its incidence and burden will increase in our aging Western society. The disease is clinically heterogeneous, ranging from death within 2-3 years to indolent. CLL is a prime example where outcome is influenced by both genetic variation and microenvironmental factors acting on the cancer cells. Current standard treatment options, but also (combinations with) novel targeted drugs and immunotherapies about to enter the clinic, offer no curative perspective. These insights are based on recent molecular insight which demonstrated 1) new CLL cancer genes of unknown function, linked with treatment resistance, 2) early occurrence of minor subclones known to predispose to resistance, 3) emergence of novel mutations under treatment with new targeted drugs, 4) microenvironmental and signaling hetereogeneity which is linked with immune suppression and tumor escape.
Hypothesis: despite promising new therapeutics, resistance development due to tumor and microenvironmental heterogeneity will remain an obstacle for long-term clinical success in CLL
Aim:  Lasting cure of CLL by combination treatment, based on molecular understanding of patient-specific genetic and microenvironmental heterogeneity.
Methods: an integrated approach with various modules that feed into and reinforce each other:
1. NGS characterization of leukemic heterogeneity and subclonality
a. From untreated and treatment resistant patient samples, various timepoints
b. From clinical trial samples in relation to outcome after different treatments
c. From different compartments, PB, LN, BM and Richters tranformation
d. From different locations within the same compartment
2. State of the art in vitro and in vivo models to develop and assess tailored combination strategies
a. Human models incorporating relevant accessory cell types and distinct CLL genotypes
b. Murine models incorporating relevant accessory cell types and distinct treatments
3. Functional analysis of (novel) CLL mutations in relation to microenvironment and treatment resistance
a. Genome wide impact (RNA, proteomics) of relevant mutations  in patient samples in response to treatment(s)
b. Development and implementation of biomarkers for resistance
c. Mechanistic analyses of individual mutations in genetically modified human and murine cells
Expected results and potential impact. The results from this international, concerted effort will bring lasting cures for CLL within reach of clinical reality. The integration of expert groups across the EU with complementary expertise to address current clinical as well as fundamental questions provides a platform for scientific and clinical training of the next generation of clinicians and researchers. The impact of the results obtained will extend beyond the participating research groups and beyond CLL.

(Project funded under JTC 2014)


Fourth Joint Transnational Call 2017 (JTC 2017)

on: Translational Research on Rare Cancers

12 projects selected for funding

visit the page


Newsletter 7, October 2018

Newsletter 6, June 2108
Newsletter 5, March 2018
Newsletter 4, December 2017
Newsletter 3, September 2017
Newsletter 2, April 2017
Newsletter 1, December 2016

To subscribe to TRANSCAN-2 newsletter mailing list please send an email to: This email address is being protected from spambots. You need JavaScript enabled to view it.

eu flagship

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643638.